Leerink analyst Geoffrey Porges sees a light at the end of the tunnel for Big Biotech.
In a note published today, he predicted that the stocks in his coverage area could shake off the doldrums, and climb 25% to 30% in theIllustration: Getty Images
next year, if “the group captures a re-rating back to the long term average relative multiple, and our generally positive view of the near and long term revenue and earnings outlook materializes.”
